Bristol-Myers secures FDA approval for new dosing of cancer drug Opdivo

This article was originally published here

The US Food and Drug Administration (FDA) has approved a four-week dosing schedule for Bristol-Myers Squibb’s Opdivo cancer drug.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply